Developer docs
API playgroundTry for free, no card

Search company profiles

Celsius42

Full company profile

uuid002joe3

Namestring
Celsius42
Legal namestring
Celsius42 GmbH
Websiteurl
celsius42.de
Company typeenum
Private
Founded yearint
2006
Descriptiontext

Celsius42 GmbH is a privately-held German medical-technology company headquartered in Eschweiler that develops, manufactures, and distributes the Celsius TCS (Tumor Cell Solution) — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment. The system differentiates through a dual active electrode architecture with variable electrode sizes, automatic electrode recognition, hydraulic patient positioning, high-capacity water cooling for deep tissue penetration, programmable treatment protocols, and a Linux-based operating system for data security. It is indicated for a broad range of solid tumors across gynecological, organ-based (brain, liver, lung, kidney, pancreas, esophagus), gastrointestinal, sarcoma, and melanoma indications in both curative and palliative settings.

The company operates an enterprise field-sales model targeting hospitals with radiotherapy departments and oncology outpatient centers, combining direct sales, mandatory maintenance agreements (required under the German Medical Device Act), and downstream per-treatment-session economics (German GOÄ billing at €145.14 per session accrues to providers). International reach is delivered through a wholly-owned Korean subsidiary (Celsius42 Korea LTD in Gunpo) serving Asia and a strategic long-term alliance with Dubai-based Lootah Group covering the Middle East, Africa, and India, with a planned Dubai office. Named clinical reference sites include Charité University Hospital Berlin, Clinic St. Georg Bad Aibling, and the KSA-KSB Cancer Center Aarau in Switzerland.

Celsius42 was founded in 2006, underwent insolvency-driven restructuring of its legacy Celsius42+ GmbH entity in 2016 due to new medical-device regulatory requirements, and re-emerged under new leadership in 2017-2018 with Christian Hartmann as CEO. The company relocated to larger facilities in Eschweiler in February 2019 (incorporating a training academy), achieved its best half-year financial result ever in H1 2020 despite COVID-19 disruption, and reported 1-10 employees on standard business profiles. No external institutional funding, venture capital, or public market activity is disclosed.

Short descriptiontext

Celsius42 GmbH, a private German medical-technology company, develops and sells the Celsius TCS — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used by hospitals and oncology centers as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersEschweiler, Germany
HQ citystring
Eschweiler
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices4 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
regional deep hyperthermia, oncology medical devices, cancer adjuvant therapy, hyperthermia treatment systems, medical radiofrequency equipment
Industry1 code
PRIMARYHLAKAFAC
Radiation Oncology
NAICS code1 code
  • Electromedical and Electrotherapeutic Apparatus Manufacturing334510
SIC code1 code
  • Electromedical & Electrotherapeutic Apparatus3845
Product category
Oncology Hyperthermia Medical Devices
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Medical Device Sales (Celsius TCS Hyperthermia System)
TypeHardware Sales
Description

Sale of the Celsius TCS hyperthermia medical device to hospitals and oncology centers. The system includes hardware components and requires mandatory maintenance agreements.

celsius42.de
2Mandatory Maintenance Agreements
TypeManaged Services
Description

Due to the complex nature of the medical device under the Medical Device Act (Medizinproduktgesetz), mandatory maintenance is required during the warranty period. Maintenance agreements are obligatory upon acquisition and include support services, telephone hotline, and proactive maintenance.

celsius42.de
3Per-Treatment Session Billing
TypeTransaction Fee
Description

Regional deep hyperthermia treatments are typically billed according to the German medical fee schedule (GOÄ) at 145.14 Euro per treatment session (GOÄ number 5854). Revenue accrues per treatment delivered to patients.

celsius42.de
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels4 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel
Pricing details1 tier
1Per treatment session: 145.14 Euro (GOÄ 5854)
ModelUnit PricingBilling cadencePay-as-you-go
Notes

Regional deep hyperthermia costs are typically calculated according to the simple rate of GOÄ (German medical fee schedule) at 145.14 Euro per treatment session. Health insurance reimbursement requires individual application; German Federal Court ruled in 2006 that one insurance provider must cover treatment costs in a specific case.

celsius42.de
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1Celsius TCS – Tumor Cell Solution
Description

The TCS (Tumor Cell Solution) hyperthermia system for regional deep hyperthermia treatment, using 13.56 MHz RF frequency technology to heat tumor tissue as an adjunct to radiotherapy and chemotherapy.

celsius42.de
Core offering1 text field

Celsius42 develops, manufactures, and sells the Celsius TCS (Tumor Cell Solution), a 13.56 MHz radiofrequency capacitive hyperthermia medical device for regional deep hyperthermia cancer treatment. The system is sold to hospitals and oncology outpatient centers as a complementary therapy to enhance the effectiveness of radiotherapy and chemotherapy for solid tumors, with mandatory maintenance agreements and per-treatment session billing.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Radiotherapy effectiveness increased by factor of 1.2 to 5 when combined with hyperthermia
+2 more records
Product overview1 text field

Celsius42 offers a single unified medical device product: the Celsius TCS (Tumor Cell Solution) hyperthermia system. This is a capacitive regional deep hyperthermia medical device designed as a complementary cancer therapy to enhance the effectiveness of radiation and chemotherapy. The system operates at a carrier frequency of 13.56 MHz and features dual active electrodes with intelligent recognition, hydraulic positioning arms, programmable treatment protocols, and sustainable water cooling for effective deep-tissue heating. The product is supported by workflow management software, patient databases, and medical documentation features, all running on a Linux-based operating system.

Product and service1 record
1Celsius TCS (Tumor Cell Solution)
CategoryOncology hyperthermia medical device
Description

A 13.56 MHz capacitive radiofrequency regional deep hyperthermia medical device for cancer treatment, sold to hospitals with radiotherapy departments and oncology outpatient centers. Features dual active electrodes, variable electrode sizes, high-capacity water cooling, automatic electrode recognition, patient safety monitoring, and individually programmable treatment protocols on a Linux-based platform. Indicated for solid tumors including gynecological malignancies, organ tumors, deep-seated lesions, lymph node metastases, gastrointestinal tumors, sarcomas, and melanomas, used as an adjunct to radiotherapy and chemotherapy.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-05-11
Description

Long-term and extensive strategic cooperation between Celsius42 and Dubai-based Lootah Group to expand hyperthermia cancer treatment in Middle East, Africa, and India. Lootah Group, led by Ibrahim Saeed Lootah, is recognized as a pioneer in broad-based core technologies with 37+ manufacturing facilities and owns a medical university in Dubai. Partnership aims to establish hyperthermia as essential component of medical education and build dedicated cancer treatment centers.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers7 records
TypeDirect peer
Description

Frankfurt-listed German company using magnetic nanoparticle-based thermotherapy (NanoTherm) for glioblastoma and prostate cancer; alternative technology approach in the same oncology-hyperthermia category.

TypeBroad incumbent
Description

Swedish radiation oncology and radiosurgery vendor (Versa HD, Elekta Infinity, Leksell Gamma Knife). Competes for radiotherapy department capital budgets that Celsius42 depends on for placement.

3Pyrexar Medical
TypeDirect peer
Description

US-based manufacturer of regional and superficial hyperthermia systems (BSD-500, BSD-2000). Direct competitor to Celsius42's TCS in the same capacitive RF deep hyperthermia category for oncology.

TypeBroad incumbent
Description

Maker of CyberKnife and TomoTherapy radiation therapy systems; broad incumbent in radiation oncology whose customer sites are the natural channel for Celsius42's adjunct hyperthermia.

TypeDirect peer
Description

Hungarian/German manufacturer of regional deep hyperthermia devices (EHY series) using capacitive RF at 13.56 MHz — the closest technology and market overlap with Celsius TCS.

TypeBroad incumbent
Description

Global leader in linear accelerators and radiotherapy software (TrueBeam, Ethos, ARIA). A broad incumbent whose installed base defines where hyperthermia adjuncts like Celsius TCS are sold.

TypeDirect peer
Description

German specialty manufacturer of hyperthermia systems for oncology; competes head-to-head with Celsius42 in the DACH radiotherapy clinic segment.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries2 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Celsius42

Oncology Hyperthermia Medical Devicescelsius42.de

Celsius42 GmbH, a private German medical-technology company, develops and sells the Celsius TCS — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used by hospitals and oncology centers as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment.

What Celsius42 does

Celsius42 GmbH is a privately-held German medical-technology company headquartered in Eschweiler that develops, manufactures, and distributes the Celsius TCS (Tumor Cell Solution) — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment. The system differentiates through a dual active electrode architecture with variable electrode sizes, automatic electrode recognition, hydraulic patient positioning, high-capacity water cooling for deep tissue penetration, programmable treatment protocols, and a Linux-based operating system for data security. It is indicated for a broad range of solid tumors across gynecological, organ-based (brain, liver, lung, kidney, pancreas, esophagus), gastrointestinal, sarcoma, and melanoma indications in both curative and palliative settings.

The company operates an enterprise field-sales model targeting hospitals with radiotherapy departments and oncology outpatient centers, combining direct sales, mandatory maintenance agreements (required under the German Medical Device Act), and downstream per-treatment-session economics (German GOÄ billing at €145.14 per session accrues to providers). International reach is delivered through a wholly-owned Korean subsidiary (Celsius42 Korea LTD in Gunpo) serving Asia and a strategic long-term alliance with Dubai-based Lootah Group covering the Middle East, Africa, and India, with a planned Dubai office. Named clinical reference sites include Charité University Hospital Berlin, Clinic St. Georg Bad Aibling, and the KSA-KSB Cancer Center Aarau in Switzerland.

Celsius42 was founded in 2006, underwent insolvency-driven restructuring of its legacy Celsius42+ GmbH entity in 2016 due to new medical-device regulatory requirements, and re-emerged under new leadership in 2017-2018 with Christian Hartmann as CEO. The company relocated to larger facilities in Eschweiler in February 2019 (incorporating a training academy), achieved its best half-year financial result ever in H1 2020 despite COVID-19 disruption, and reported 1-10 employees on standard business profiles. No external institutional funding, venture capital, or public market activity is disclosed.

Celsius42 firmographics

Firmographics
Name
Celsius42
Legal name
Celsius42 GmbH
Website
https://celsius42.de
Company type
Private
Founded year
2006
Operating status
Operating
Headcount range
1–10 employees
Short description
Celsius42 GmbH, a private German medical-technology company, develops and sells the Celsius TCS — a 13.56 MHz capacitive radiofrequency regional deep hyperthermia system used by hospitals and oncology centers as an adjuvant to radiotherapy and chemotherapy in solid-tumor cancer treatment.
Ownership category
akta.pro rank

Celsius42 industry classification

Industry
Product category
Oncology Hyperthermia Medical Devices
NAICS
Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)
SIC
Electromedical & Electrotherapeutic Apparatus (3845)
akta.pro industry
PRIMARYHLAKAFAC
Radiation Oncology

Keywords

  • Regional deep hyperthermia
  • Oncology medical devices
  • Cancer adjuvant therapy
  • Hyperthermia treatment systems
  • Medical radiofrequency equipment

Where Celsius42 is headquartered

Location

Headquarters

HQ city
Eschweiler
HQ country
Germany
HQ region
Europe

Offices4 records

Markets served

Celsius42 business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Supply Chain, Marketing or Sales, Operations, Personnel

Revenue model

  1. Medical Device Sales (Celsius TCS Hyperthermia System): Sale of the Celsius TCS hyperthermia medical device to hospitals and oncology centers. The system includes hardware components and requires mandatory maintenance agreements.
  2. Mandatory Maintenance Agreements: Due to the complex nature of the medical device under the Medical Device Act (Medizinproduktgesetz), mandatory maintenance is required during the warranty period. Maintenance agreements are obligatory upon acquisition and include support services, telephone hotline, and proactive maintenance.
  3. Per-Treatment Session Billing: Regional deep hyperthermia treatments are typically billed according to the German medical fee schedule (GOÄ) at 145.14 Euro per treatment session (GOÄ number 5854). Revenue accrues per treatment delivered to patients.

Pricing tiers

ModelBillingPrice
Unit PricingPay-as-you-goPer treatment session: 145.14 Euro (GOÄ 5854)

Go-to-market motion1 record

Distribution channels4 records

Marketing channels5 records

Celsius42 product offering

Product offering

Core offering

Celsius42 develops, manufactures, and sells the Celsius TCS (Tumor Cell Solution), a 13.56 MHz radiofrequency capacitive hyperthermia medical device for regional deep hyperthermia cancer treatment. The system is sold to hospitals and oncology outpatient centers as a complementary therapy to enhance the effectiveness of radiotherapy and chemotherapy for solid tumors, with mandatory maintenance agreements and per-treatment session billing.

Product overview

Celsius42 offers a single unified medical device product: the Celsius TCS (Tumor Cell Solution) hyperthermia system. This is a capacitive regional deep hyperthermia medical device designed as a complementary cancer therapy to enhance the effectiveness of radiation and chemotherapy. The system operates at a carrier frequency of 13.56 MHz and features dual active electrodes with intelligent recognition, hydraulic positioning arms, programmable treatment protocols, and sustainable water cooling for effective deep-tissue heating. The product is supported by workflow management software, patient databases, and medical documentation features, all running on a Linux-based operating system.

Differentiator

Problem solved

Functional benefit

Brands

  • Celsius TCS – Tumor Cell Solution: The TCS (Tumor Cell Solution) hyperthermia system for regional deep hyperthermia treatment, using 13.56 MHz RF frequency technology to heat tumor tissue as an adjunct to radiotherapy and chemotherapy.

Products and services

  • Celsius TCS (Tumor Cell Solution) A 13.56 MHz capacitive radiofrequency regional deep hyperthermia medical device for cancer treatment, sold to hospitals with radiotherapy departments and oncology outpatient centers. Features dual active electrodes, variable electrode sizes, high-capacity water cooling, automatic electrode recognition, patient safety monitoring, and individually programmable treatment protocols on a Linux-based platform. Indicated for solid tumors including gynecological malignancies, organ tumors, deep-seated lesions, lymph node metastases, gastrointestinal tumors, sarcomas, and melanomas, used as an adjunct to radiotherapy and chemotherapy.

Quantifiable outcome

  • Radiotherapy effectiveness increased by factor of 1.2 to 5 when combined with hyperthermia
  • +2 more outcomes

Companies that use Celsius42

Customer profile

Named customers3 records

Segments2 records

Ideal customer profiles1 record

Celsius42 technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

Celsius42 partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Lootah GroupcoreStrategic or Co-development Partner · 11 May 2019Long-term and extensive strategic cooperation between Celsius42 and Dubai-based Lootah Group to expand hyperthermia cancer treatment in Middle East, Africa, and India. Lootah Group, led by Ibrahim Saeed Lootah, is recognized as a pioneer in broad-based core technologies with 37+ manufacturing facilities and owns a medical university in Dubai. Partnership aims to establish hyperthermia as essential component of medical education and build dedicated cancer treatment centers.

Scale indicators3 records

Recent moves7 records

Expansion highlights5 records

Celsius42 competitors and assessment

Company assessment

Direct peers

  • MagForce AG: Frankfurt-listed German company using magnetic nanoparticle-based thermotherapy (NanoTherm) for glioblastoma and prostate cancer; alternative technology approach in the same oncology-hyperthermia category.
  • Pyrexar Medical: US-based manufacturer of regional and superficial hyperthermia systems (BSD-500, BSD-2000). Direct competitor to Celsius42's TCS in the same capacitive RF deep hyperthermia category for oncology.
  • Oncotherm: Hungarian/German manufacturer of regional deep hyperthermia devices (EHY series) using capacitive RF at 13.56 MHz — the closest technology and market overlap with Celsius TCS.
  • Dr. Sennewald Medizintechnik GmbH: German specialty manufacturer of hyperthermia systems for oncology; competes head-to-head with Celsius42 in the DACH radiotherapy clinic segment.

Broad incumbents

  • Elekta: Swedish radiation oncology and radiosurgery vendor (Versa HD, Elekta Infinity, Leksell Gamma Knife). Competes for radiotherapy department capital budgets that Celsius42 depends on for placement.
  • Accuray: Maker of CyberKnife and TomoTherapy radiation therapy systems; broad incumbent in radiation oncology whose customer sites are the natural channel for Celsius42's adjunct hyperthermia.
  • Varian Medical Systems (Siemens Healthineers): Global leader in linear accelerators and radiotherapy software (TrueBeam, Ethos, ARIA). A broad incumbent whose installed base defines where hyperthermia adjuncts like Celsius TCS are sold.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Celsius42 social profiles

Digital presence

Celsius42 financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Celsius42 leadership team

Management profile

Number of profiles

Profiles2 records

Celsius42 subsidiaries and ownership

Company hierarchy

Subsidiaries2 records

Celsius42 funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Celsius42 M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Celsius42

What does Celsius42 do?

Celsius42 develops, manufactures, and sells the Celsius TCS (Tumor Cell Solution), a 13.56 MHz radiofrequency capacitive hyperthermia medical device for regional deep hyperthermia cancer treatment. The system is sold to hospitals and oncology outpatient centers as a complementary therapy to enhance the effectiveness of radiotherapy and chemotherapy for solid tumors, with mandatory maintenance agreements and per-treatment session billing.

Is Celsius42 a public or private company?

Celsius42 is a private company. It is classified as founder individual operated bootstrapped and is currently operating.

When was Celsius42 founded?

Celsius42 was founded in 2006. It employs 1 to 10 people.

Where is Celsius42 based?

Celsius42 is headquartered in Eschweiler, Germany, in the Europe region.

How does Celsius42 make money?

Three revenue lines are on record. Medical Device Sales (Celsius TCS Hyperthermia System) is the primary driver. The others are mandatory Maintenance Agreements and per-Treatment Session Billing.

Who are Celsius42's main competitors?

Direct peers on record are MagForce AG, Pyrexar Medical, Oncotherm and Dr. Sennewald Medizintechnik GmbH. Broad incumbents are Elekta, Accuray and Varian Medical Systems (Siemens Healthineers).

Does Celsius42 have an API?

No public API is recorded for Celsius42.

What industry is Celsius42 in?

Celsius42's product category is Oncology Hyperthermia Medical Devices. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology. Its NAICS code is 334510 and its SIC code is 3845.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales